<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04996082</url>
  </required_header>
  <id_info>
    <org_study_id>PO21044</org_study_id>
    <nct_id>NCT04996082</nct_id>
  </id_info>
  <brief_title>Skin Fibrosis Analysis by Raman Spectroscopy in Systemic Sclerosis</brief_title>
  <acronym>RAMSES</acronym>
  <official_title>Skin Fibrosis Analysis by Raman Spectroscopy in Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Reims</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Reims</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systemic sclerosis (SSc) is a rare connective tissue disease characterized by a high clinical&#xD;
      heterogeneity with unpredictable evolution that could engage functional and life-threatening&#xD;
      prognosis. Most of patients develop skin fibrosis gradually spreading. Two clinical distinct&#xD;
      forms are described according to the extension of skin fibrosis: limited (lSSc) and diffuse&#xD;
      (dSSc) SSc. It is now admitted that a spreading of skin fibrosis is associated with poor&#xD;
      prognosis. This disease can be complicated by pulmonary arterial hypertension (PAH),&#xD;
      interstitial lung disease (ILD) and scleroderma renal crisis (SRC) representing the main&#xD;
      causes of death in SSc. Usually, PAH is associated with lSSc, and ILD and SRC are associated&#xD;
      with dSSc. Prognosis is also different regarding skin phenotype with a higher mortality rate&#xD;
      in dSSc.&#xD;
&#xD;
      An easy score, called modified Rodnan skin score, is commonly used in clinical practice to&#xD;
      evaluate the spreading and severity of skin fibrosis, but this score is hardly reproducible.&#xD;
      Ultrasound can be used to measure skin thickness and is more reproducible than the Rodnan&#xD;
      skin score. Nevertheless, non-invasive analysis of fibrosis composition in different areas is&#xD;
      not possible with these two technics.&#xD;
&#xD;
      Thus, in this study we will investigate Raman spectroscopy, a non-invasive technic based on&#xD;
      the interaction of a low-intensity laser with matter.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Raman spectroscopy will be performed on patients with SSc, according to the ACR criteria, and&#xD;
      control patients without SSc, on 3 different areas of the skin. Patients with SSc and&#xD;
      controls will be matched by gender and age. These measures will be performed at 6 months, 12&#xD;
      months, 24 months and 36 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Raman spectroscopy</measure>
    <time_frame>at 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Raman spectroscopy</measure>
    <time_frame>at 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Raman spectroscopy</measure>
    <time_frame>at 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Raman spectroscopy</measure>
    <time_frame>at 36 months</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Validation of Raman Spectroscopy Usefulness in Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>Systemic sclerosis group</arm_group_label>
    <description>Patients with systemic sclerosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Systemic sclerosis group</arm_group_label>
    <description>Patients without systemic sclerosis</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with or without systemic sclerosis, according to ACR criteria, older than&#xD;
        18-years-old&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        inclusion criteria :&#xD;
&#xD;
          -  patients with SSc, according to ACR criteria&#xD;
&#xD;
          -  older than 18-years-old exclusion criteria :&#xD;
&#xD;
          -  younger than 18-years-old&#xD;
&#xD;
          -  patient protected by law&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amélie SERVETTAZ</last_name>
    <phone>03 26 83 27 69</phone>
    <phone_ext>0033</phone_ext>
    <email>aservettaz@chu-reims.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Damien JOLLY</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Amélie SERVETTAZ</last_name>
      <phone>03 26 83 27 69</phone>
      <phone_ext>0033</phone_ext>
      <email>aservettaz@chu-reims.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Systemic sclerosis</keyword>
  <keyword>Raman spectroscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

